Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : U.S. CDC advisers could vote on Pfizer COVID-19 vaccine booster on Thursday

09/22/2021 | 02:48pm EDT

Sept 22 (Reuters) - A U.S. Centers for Disease Control and Prevention advisory panel could vote on the use of a third shot of Pfizer Inc and partner BioNTech SE's COVID-19 vaccine on Thursday, an agency official said at a public meeting of the panel on Wednesday.

The CDC's Advisory Committee on Immunization Practices (ACIP) is meeting on Sept 22-23 to weigh which populations would most benefit from a third shot as it awaits a decision on authorization by the U.S. Food and Drug Administration.

Pfizer has asked the FDA to approve the third shot for all people aged 16 and over, but a panel of outside advisors to the FDA last Friday said there was only evidence for a shot being needed by people aged 65 and older. The FDA has not yet said how it plans to proceed.

The CDC panel considered presentations from staff showing how the vaccine worked in different age groups and populations, including older adults, those whose jobs put them at increased risk for exposure such as healthcare workers, and adults with underlying medical conditions.

Several of the presentations showed vaccine efficacy in older adults against hospitalization was falling, impacted both by the Delta variant and possible waning of vaccine efficacy over time.

Pfizer officials reviewed the case it presented last week to the FDA advisory panel arguing that a booster is needed for all populations.

CDC staff also reviewed U.S. studies on vaccine effectiveness across U.S. populations and found significant declines in effectiveness against infection for vaccines based on messenger RNA technology during the period when the Delta variant was predominant.

The studies also showed protection from hospitalization declined more in those vaccinated with the Pfizer vaccine than the one made by Moderna Inc. during the time when the Delta variant was predominant.

Similar patterns of reduced vaccine effectiveness were seen in the general adult population. (Reporting by Manojna Maddipatla in Bengaluru Editing by Sonya Hepinstall)


© Reuters 2021
All news about MODERNA, INC.
11:50aSANOFI : says its flu vaccine can be co-administered with Moderna's COVID-19 shot
RE
11:42aFDA OFFICIAL : Booster announcements coming Wednesday
AQ
04:44aKAROLINSKA INSTITUTET : Two COVID-19 Vaccine Doses Increase Airway Antibodies After Infect..
MT
03:02aMODERNA : Germany may miss COVID-19 vaccine donation goal, blames manufacturers
RE
10/19MODERNA : U.S. FDA to recommend Pfizer, Moderna boosters for people 40 and older -CNN
RE
10/19MODERNA : U.S. administers 409.4 mln doses of COVID-19 vaccines - CDC
RE
10/19INSIDER SELL : Moderna
MT
10/19US expected to authorize mix-and-match COVID booster shots
AQ
10/19MODERNA : Germany may miss COVID-19 vaccine donation goal, blames manufacturers
RE
10/19MODERNA : Germany may miss COVID-19 vaccine donation goal, blames manufacturers
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 335 M - -
Net income 2021 12 514 M - -
Net cash 2021 12 947 M - -
P/E ratio 2021 11,2x
Yield 2021 -
Capitalization 135 B 135 B -
EV / Sales 2021 5,99x
EV / Sales 2022 5,25x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 333,61 $
Average target price 299,31 $
Spread / Average Target -10,3%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.219.34%134 660
LONZA GROUP AG27.07%58 240
IQVIA HOLDINGS INC.38.99%47 715
SEAGEN INC.-0.54%31 691
CELLTRION, INC.-39.28%25 332
ALNYLAM PHARMACEUTICALS, INC.58.95%24 553